Jon Lim, MRCP PhD

Major study launched to make advanced cancer treatments safer for patients A major new UK study, led by The Christie NHS Foundation Trust and The University of Manchester, has been launched to help patients with cancer better tolerate cutting-edge immunotherapy treatments li...

Hear more about RISE + why tackling safety/toxicity in advanced therapies is centre to our programme.

We're humbled to hear from Elkie Mellor, who generously shared her lived experience. Voices like hers are a powerful reminder of why this work matters & will continue to motivate everything we do.

RISE Manchester | LinkedIn RISE Manchester | 44 followers on LinkedIn. Making advanced cancer therapies safer through science, innovation and partnership. | RISE (Reducing Immune Stress from Excess cytokine release in advanced ...

🚀 Excited to share the launch of our RISE consortium.

RISE unites NHS, academic & industry partners to tackle immune-related toxicities in advanced cancer therapies, incl. CRS & neurotoxicity - centred around patient safety + quality of life.

Funded by @ukri.org MRC Prosperity Partnership Award.

'Neoadjuvant immunotherapy continues to rewrite our understanding of anticancer immunity'

Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇

This is the very ethos of MANIFEST: linking academia, NHS, biotech & pharma to solve the hardest questions in IO.

🔍 Want to learn more about MANIFEST?
🌐 www.manifest-io.org.uk
🤝 @manifest-cirrp.bsky.social
🔗 Our programmes:

✨ #ESMOImmuno25

@turajliclab.bsky.social presented the MANIFEST platform, recent progress & our ambitions at ESMO IO Congress here in London.

The message from the 'Special Session with Industry': cross-sector collaboration is critical to accelerate discovery & develop safer/effective therapies.

Really looking forward to catching up with colleagues and friends at #ESMOImmuno25 in London.

If you’re attending, please stop by our team’s poster - presented by our Specialist Pharmacist Ragini Jethra. We highlight new insights from our systematic review on the safety profile of TIL therapy.

If you're looking for careers support our 2026 mentoring scheme applications close on December 10 2025. Learn more here: www.immunology.org/careers/bsi-...

🩺 Fantastic opportunity for #YoungOncologists: ICF-ESMO programme for an 8-week observership.

We've excellent opportunities here in Manchester & would be happy to support (✉️: the-christie.observers@nhs.net).

@christieinstitute.bsky.social
@myesmo.bsky.social

📥 For more info (due 25 Jan 2026) 👇

Excited about not one but 2 fantastic conferences in Manchester! So timely as cell therapies are on the standard care horizon!

Please join us, and share with your colleagues.

@beckilee.bsky.social @turajliclab.bsky.social @lydiabeckeriii.bsky.social @fbmh-uom.bsky.social @uom-dcs.bsky.social @manchester.ac.uk @christieinstitute.bsky.social @cruknbc.bsky.social @cruk-mi.bsky.social @mcrcnews.bsky.social

...and don’t miss our TIL Summit 2026, taking place the day before (11 Mar 2026), also at the Midland Hotel.

A dedicated forum bringing together UK & international leaders to discuss TIL therapy, manufacturing, biomarkers, and next-generation trials 👇

Join us in Manchester for a unique, cross-disciplinary meeting to accelerate innovation from bench to bedside.

🧬 Cutting-edge science
🧫 Tumour immunology & microenvironment
🧪 Advanced therapies, biomarkers, early detection
🏥 Translational pipelines & clinical implementation
🤝 Networking

Home Lab to Life: Innovations in Melanoma is a UK conference in Manchester on cutting-edge melanoma research, translational science and advances in treatments.

⏰ Calling all melanoma enthusiasts!

The abstract submission deadline for the inaugural “Lab to Life: Innovations in Melanoma Research Conference UK 2026” has been extended to 19 December 2025!

Happening 12-13 March 2026 at The Midland Hotel, Manchester.

Submit your abstract and register here:

Diagram showing CAR T-cells and T-cell therapies for cancer. It details the structure of chimeric antigen receptors, engineered CAR T-cells targeting tumor antigens, and tumor-infiltrating lymphocytes.

🧬 CAR T treatments improve overall survival for patients with large B-cell lymphoma and progression-free survival for patients with multiple myeloma.

Save this Review for your bibliography:
ja.ma/49HHc34

Unlocking TIL Therapy: A New Era for Melanoma Care in the UK Join us for the Unlocking TIL Therapy: A New Era for Melanoma Care in the UK onsite at The Midland Hotel Manchester

Proudly delivered, label-free, in collaboration with @christieinstitute.bsky.social & The Christie Charity.

Limited places - please register early.
Looking forward to seeing many of you there! 🌟

🔗 Event link 👇

✨ What to expect:
• Biomarkers & the tumour microenvironment in predicting TIL response
• Core science and clinical development of TIL therapy
• Patient selection, coordination & toxicity management
• Challenges of scaling TIL therapy across the NHS

This inaugural event brings together UK & international leaders to explore the science, clinical practice + infrastructure behind TIL (Tumour-Infiltrating Lymphocyte) therapy as it enters routine melanoma care.

Programme and speaker line-up will be revealed soon...

🚀 Save the Date!

We’re excited to launch our flagship TIL Summit in Manchester: "Unlocking TIL Therapy: A New Era for Melanoma Care in the UK"

🗓 11 March 2026
📍 The Midland Hotel, Manchester

End of an era! @marianapdc.bsky.social is one of the most talented scientists I have ever met; beyond that a super good friend 🙌. So honoured to have overlapped in the lab with you, and see you shine and rise to all the successes you so deserve. Thanks for all the wonderful times.

All the best! 💫

Hunter syndrome: Boy with rare condition amazes doctors after world-first gene therapy Oliver has an inherited condition called Hunter syndrome, which causes progressive damage to the body and brain.

The parents of a three-year-old boy born with a devastating, life-limiting genetic condition say they are now excited for his future after he received a revolutionary stem cell gene therapy treatment developed by researchers at the University of Manchester.
www.bbc.co.uk/news/article...

Levy on international students’ tuition fees not in best interest of UK, says leader of top university Duncan Ivison, president of Manchester University, says government’s 6% surcharge plan will ‘hurt the sector’

Levy on international students’ tuition fees not in best interest of UK, says @duncanivison.bsky.social, president and VC of @manchester.ac.uk
More from @theguardian.com
bit.ly/4r1save
#education #educationnews

MI/25/63 Associate Scientist | Cancer Research UK Manchester Institute We are seeking a highly motivated and accomplished Associate Scientist to help lead and shape the programme. You will act as an operational deputy to Professor Samra Turajlic, helping to bridge activi...

Fantastic opportunity from @turajliclab.bsky.social! 🚀

The CanDy Lab is recruiting an Associate Scientist to drive cutting-edge cancer research across @cruk-mi.bsky.social and @crick.ac.uk.

A rare chance to lead, grow, and shape high-impact science 👇
www.cruk.manchester.ac.uk/career/mi-25...

🚨 Save the Date!
Next #ChristieFellows session:

“Preparing a Grant Proposal for PhD or Research Projects”
🎤 Dr Jamie Weaver
🗓️ Tue 18 Nov 2025 | 12:30–13:30
📍 Seminar 4&5, Edu Centre

Learn how to pitch your idea & navigate the grant process from an early-career clinical academic.

#TeamManchester 🐝

We were proud to see #TeamManchester present at over 10 sessions & 20+ posters at #ESMO2025.

Well done to everyone involved in representing the MCRC on this international stage & demonstrating the commitment of our researchers & clinicians!🐝

See you all in Spain for #ESMO26! 🇪🇸

A brilliant example of the strength of #TranslationalResearch in Manchester - spanning biology, prevention, and real patient impact.

Huge congratulations, Sacha, Rob and team at the @mcr-breastcentre.bsky.social, @uom-dcs.bsky.social and The Christie. 👏

#TeamManchester 🐝
@mcrcnews.bsky.social

New study uncovers potential way to prevent breast cancer in pre-menopausal women A University of Manchester study funded by Breast Cancer Now and supported by Prevent Breast Cancer, reveals a drug approved for use in other conditions could be repurposed to prevent breast cancer in...

So proud of my colleague Sacha Howell on this latest @nature.com publication reporting on the Breast Cancer-Anti-Progestin Prevention Study 1 (BC-APPS1) - many years in the making: www.nature.com/articles/s41...

Press release from The University of Manchester:
www.manchester.ac.uk/about/news/n...

#ESMO25: Positive efficacy results without safety concerns seen with NW-301V, a TCR-T therapy targeting KRAS G12V, in patients with KRAS G12V-mutant advanced #GICancer in a phase I #ClinicalTrial.
#ESMODailyReporter🔗 https://ow.ly/jouK50XjATp


Jon Lim, MRCP PhD

We joined forces across Europe to map, connect & accelerate the development of ATMPs — gene, cell and tissue-based therapies that could transform patient care.

We make ATMP innovation faster, safer and more accessible for everyone.

👉 join4atmp.eu

#JOIN4ATMP #ATMP #HorizonEurope #HealthInnovation

CRUK MCRC PhD Taster Session 2025–2026 : Discover, Apply, Lead From Curiosity to Cure: Explore PhD Opportunities at CRUK MCRC, Meet the Researchers and Map Your Future

There’s still time to sign up for our Taster Session on Thursday 30 October to learn more about studying a #PhD in Cancer Sciences.

⏰ Learn about our application process
🧑‍ Hear from current students
🐝 Learn what it’s like to study in Manchester

www.eventbrite.co.uk/e/cruk-mcrc-...

Our fourth and final day of #ESMO25! We listened to talks by Consultant & Fellow Alum Melissa Frizziero and Honorary Academic Consultant & Fellowships Specialty Lead for Medical Oncology @drjonlim.bsky.social! We also learned about the various professional development opportunities offered by ESMO 🎓